Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
29.82
+0.61 (2.09%)
At close: Oct 30, 2026, 4:00 PM EDT
29.63
-0.19 (-0.64%)
After-hours: Oct 30, 2026, 7:50 PM EDT
Xencor Revenue
Xencor had revenue of $51.22M in the quarter ending June 30, 2026, with 17.46% growth. This brings the company's total for the last twelve months to $104.97M, down -28.56% year-over-year. In the year 2025, Xencor had annual revenue of $125.58M with 13.65% growth. That makes Xencor the 22,322nd largest company in the world by revenue and 3,257th in the United States.
Revenue (ttm)
$104.97M
Revenue Growth
-28.56%
P/S Ratio
21.12
Revenue / Employee
$403,742
Employees
260
Market Cap
2.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.58M | 15.08M | 13.65% |
| Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
| Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
| Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
| Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
| Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
| Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
| Dec 31, 2018 | 40.60M | -5.55M | -12.02% |
| Dec 31, 2017 | 46.15M | -41.37M | -47.27% |
| Dec 31, 2016 | 87.52M | 59.76M | 215.25% |
| Dec 31, 2015 | 27.76M | 18.24M | 191.62% |
| Dec 31, 2014 | 9.52M | -652.00K | -6.41% |
| Dec 31, 2013 | 10.17M | 648.00K | 6.80% |
| Dec 31, 2012 | 9.52M | 2.68M | 39.06% |
| Dec 31, 2011 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.67B |
| Harmony Biosciences Holdings | 959.90M |
| Aurinia Pharmaceuticals | 311.51M |
| Maravai LifeSciences Holdings | 208.78M |
| Agios Pharmaceuticals | 98.34M |
| Precigen | 85.72M |
| Immunome | 4.02M |
| Celldex Therapeutics | 158.00K |
XNCR News
- 5 days ago - Xencor price target raised to $43 from $20 at RBC Capital - TheFly
- 5 days ago - Xencor price target raised to $40 from $29 at Truist - TheFly
- 5 days ago - Xencor price target raised to $40 from $29 at Truist - TheFly
- 5 days ago - Xencor price target raised to $45 from $30 at Wedbush - TheFly
- 5 days ago - Xencor price target raised to $45 from $35 at Barclays - TheFly
- 6 days ago - Xencor Transcript: Study update - Transcripts
- 6 days ago - Xencor Press release: Study update - Filings
- 6 days ago - Xencor Slides: Study update - Filings